Dr. Sanjay Agarwal | Diabetes and Endocrinology | Omnicuris

Home

Courses

MedShots

Survey

Verifying...

Loading, please wait...

Consult AIRA AI

About Us Contact Us FAQs Privacy Policy Terms of Use ISO

Download Our Mobile App

Copyright © 2026 Omnicuris Healthcare Pvt Ltd. All rights reserved.

"Wherever the art of Medicine is loved, there is also a love of Humanity."

Hippocrates

Made with❤️byOmnicuris

© 2026 Omnicuris Healthcare Pvt Ltd.

AIRA MedShots Profile

Dr. Sanjay Agarwal | Diabetes and Endocrinology | Omnicuris

Dr. Sanjay Agarwal

Honorary Secretary General, RSSDI

Qualification

Diabetes and Endocrinology

Location

Pune City East, Maharashtra, India

Qualification

Diabetes and Endocrinology

Location

Pune City East, Maharashtra, India

Educational Content

28 Sessions

Case Studies

Case Studies

Prevalence, Pathophysiology and Diagnosis of GERD and Diabetes

Prevalence, Pathophysiology and Diagnosis of GERD and Diabetes

GERD and Obesity Case study 2 and Discussion

GERD and Obesity Case study 2 and Discussion

GERD and Obesity Case study 1 and Discussion

GERD and Obesity Case study 1 and Discussion

GERD and Obesity Case study and Discussion

GERD and Obesity Case study and Discussion

Using Technology and Digital Solutions for Transforming Diabetes Care

Using Technology and Digital Solutions for Transforming Diabetes Care

D3 MMS Discussion 3

D3 MMS Discussion 3

Basal Insulin Optimization Approaches - Over 2 Decades in India

Basal Insulin Optimization Approaches - Over 2 Decades in India

D1 VAS Discussion 2

D1 VAS Discussion 2

Diabetes Care with Meaningful Monitoring

Diabetes Care with Meaningful Monitoring

Importance of Basal Insulin

Importance of Basal Insulin

Discussion 3

Discussion 3

Should Every Indian T2DM Patients be on SGLT2i?

Should Every Indian T2DM Patients be on SGLT2i?

The Vertis Trial and Management of T2D Emphasizing on SGLT2i

The Vertis Trial and Management of T2D Emphasizing on SGLT2i

Role of GLP1 Agonists, SGLT2 and DPP4 Inhibitors in CVOTs

Role of GLP1 Agonists, SGLT2 and DPP4 Inhibitors in CVOTs

Discussion 1

Discussion 1

Relationship between Diabetes and CVD, Risk Factors and CVOTs in T2D

Relationship between Diabetes and CVD, Risk Factors and CVOTs in T2D

Discussion 2

Discussion 2

Diabetes, Prediabetes & Cardiovascular Disease Risk

Diabetes, Prediabetes & Cardiovascular Disease Risk

Current Status of Diabetes Care in the DASG Countries

Current Status of Diabetes Care in the DASG Countries

Questions and Answers Session with Dr. Sanjay

Questions and Answers Session with Dr. Sanjay

Controlling Cardiovascular Risk in Diabetes and Residual Cardiovascular Risk

Controlling Cardiovascular Risk in Diabetes and Residual Cardiovascular Risk

Conclusion & Vote of Thanks

Conclusion & Vote of Thanks

Panel Discussion 4

Panel Discussion 4

Panel Discussion 1

Panel Discussion 1

History & Evolution of Diabetes Technology

History & Evolution of Diabetes Technology

Prevalence of CVD with Diabetes and Cardiovascular Risk Factors

Prevalence of CVD with Diabetes and Cardiovascular Risk Factors

War of basal insulins: Making the right choice

War of basal insulins: Making the right choice